A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER Meeting Abstract
| Authors: | Jhaveri, K. L.; Jeselsohn, R.; Lim, E.; Hamilton, E. P.; Yonemori, K.; Beck, J. T.; Kaufman, P. A.; Sammons, S.; Bhave, M. A.; Saura, C.; Calvo, E.; Meniawy, T.; Larson, T.; Ma, C. X.; García-Corbacho, J.; Cao, S. S.; Estrem, S. T.; Milata, J. L.; Nguyen, B.; Beeram, M. |
| Abstract Title: | A phase 1a/b trial of imlunestrant (LY3484356), an oral selective estrogen receptor degrader (SERD) in ER-positive (ER+) advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Monotherapy results from EMBER |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300079 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1021 |
| Notes: | Meeting Abstract: 1021 -- Source: Wos |
